June/July 2022, Vol 3, No 2

At the 2022 Cholangiocarcinoma (CCA) Foundation annual meeting, Ambuj Srivastava shared his experience as a current caregiver for his dad who was diagnosed with stage 2 extrahepatic CCA.

At the 2022 CCF annual meeting, 2 patients very eloquently described their respective journeys with cholangiocarcinoma (CCA) and shared their perspectives on how to best manage the disease.

Recent advances in genomic profiling and critical understanding of pathophysiology have led to the development of multiple targeted therapies in addition to chemotherapeutic agents.

Barriers exist to the adoption of precision medicine, requiring consideration of best practices and current gaps in standard practices, a recent review article suggests.